Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 3/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799022 | 1.00 | AKT1 (0.39) | AKT1NAMPTEPHX2KAT2BUSP30 | |
| SCHEMBL799561 | 1.00 | AKT1 (0.39) | AKT1NAMPTEPHX2KAT2BUSP30 | |
| SCHEMBL24314234 | 0.88 | EPHX2 (0.43) | AKT1EPHX2KAT2B | |
| SCHEMBL2743217 | 0.88 | EPHX2 (0.43) | AKT1EPHX2KAT2B | |
| SCHEMBL8280863 | 0.88 | EPHX2 (0.43) | AKT1EPHX2KAT2B | |
| SCHEMBL799013 | 0.87 | CA12 (0.39) | AKT1DRD2HTR2ADRD3SMO | |
| SCHEMBL1908825 | 0.84 | NAMPT (0.38) | NAMPTKAT2BUSP30 | |
| SCHEMBL12627952 | 0.82 | CA12 (0.31) | AKT1EPHX2 | |
| SCHEMBL25159743 | 0.82 | CA1 (0.47) | AKT1NAMPTKAT2BUSP30 | |
| SCHEMBL16078168 | 0.80 | USP30 (0.35) | NAMPTKAT2BUSP30SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111132974-B | Sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| CN-113316566-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-27 | — | — | CN | disclosed |
| CN-111132974-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-111107903-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| WO-2017186148-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE BCR-ABL INHIBITORS | ASTAR BIOTECH LLC (US) | 2017-11-02 | — | — | WO | disclosed |
| US-9670222-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20120016122-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-19 | — | — | US | disclosed |
| US-20120016131-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-19 | — | — | US | disclosed |
| US-20120010407-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010406-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| US-8022059-B2 | Indazole acrylic acid amide compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100256108-A1 | INDAZOLE ACRYLIC ACID AMIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010070032-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
| US-20090182142-A1 | Aromatic Compound | FURUKUBO SHIGERU | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010407-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | AKT1 183/4885NAMPT 2727/4885EPHX2 2480/4885 |
| US-20120004252-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | AKT1 3582/4885NAMPT 2130/4885EPHX2 527/4885 |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | AKT1 183/4885NAMPT 2727/4885EPHX2 2480/4885 |
| US-20120016122-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | AKT1 183/4885NAMPT 2727/4885EPHX2 2480/4885 |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | AKT1 183/4885NAMPT 2727/4885EPHX2 2480/4885 |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | ABL1, PRKDC, PRKACA | AKT1 398/4885NAMPT 4340/4885EPHX2 3336/4885 |
| US-20120010406-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | AKT1 183/4885NAMPT 2727/4885EPHX2 2480/4885 |
| US-20120016131-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | AKT1 183/4885NAMPT 2727/4885EPHX2 2480/4885 |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | MITF, PRKDC, PRKACA | AKT1 816/4885NAMPT 3010/4885EPHX2 3170/4885 |
| US-20090182142-A1 | Aromatic Compound | HRH4, CCR4, HRH3 | AKT1 3372/4885NAMPT 3973/4885EPHX2 309/4885 |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | AKT1 183/4885NAMPT 2727/4885EPHX2 2480/4885 |
| US-20100256108-A1 | INDAZOLE ACRYLIC ACID AMIDE COMPOUND | KCNH2, KCNH3, KCNJ11 | AKT1 3370/4885NAMPT 3321/4885EPHX2 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.